Investigational drug · Phase 2
GT-02287
Also called: GT-02287 400, GT-02287 800
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Parkinson Disease.
Phase 2Last checked: Nov 20, 2026Latest source record: Dec 12, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "GT-02287"
First trial start
2026
May 30, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GT-02287", any sponsor or status.
Conditions studied
As listed on its trial records.
- Parkinson Disease
Approved drugs for the same conditions: Parkinson's disease · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "GT-02287" as an intervention, largest first.
- Efficacy, Safety, Tolerability, and Biomarker Effects of GT-02287 in Early Parkinson's DiseasePivotal-lookingNot yet recruiting
Gain Therapeutics, Inc.Industry
NCT07280299 · 111 participants (planned) · Start May 30, 2026 · Primary completion Jun 30, 2028
Drug: Low Dose GT-02287; High Dose GT-02287 and 1 more · For: Parkinson Disease
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Parkinson's DiseaseRecruiting
Gain Therapeutics, Inc.Industry
NCT06732180 · 20 participants (planned) · Start Feb 21, 2025 · Primary completion Nov 30, 2025
Drug: GT-02287 · For: Parkinson Disease
Sites: Darlinghurst, Australia; Kogarah, Australia; Westmead, Australia · 7 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Glucocerebrosidase Target Engagement and Therapeutic Plasma and Cerebrospinal Fluid Levels After GT-02287 Administration in Healthy Volunteers.
Pozzi R, De Sciscio M, Bosetti M, et al. · Mov Disord 2026
- Allosteric Modulation of GCase Enhances Lysosomal Activity and Reduces ER Stress in GCase-Related Disorders.
Fregno I, Pérez-Carmona N, Rudinskiy M, et al. · Int J Mol Sci 2025
Also in development for Parkinson Disease
- RadotinibSupect, IY5511Phase 33 trials
Il-Yang Pharm. Co., Ltd. · Chronic Myeloid Leukemia, Chronic Phase, CML, Chronic Phase, CML, Refractory
- CVN424Phase 32 trials
Cerevance · Parkinson Disease, Parkinson's Disease
- BHV-8000Phase 31 trial
Biohaven Therapeutics Ltd. · Parkinson Disease
- Human Dopaminergic Progenitor CellsNouvNeu001Phase 23 trials
iRegene Therapeutics Co., Ltd. · Parkinson Disease, Parkinson Disease (PD)
- AB-1005Phase 22 trials
AskBio Inc · PARKINSON DISEASE (Disorder), Parkinson Disease
- DNL151BIIB122Phase 22 trials
Denali Therapeutics Inc. · Parkinson Disease
- HBI-002Phase 22 trials
Hillhurst Biopharmaceuticals, Inc. · Parkinson Disease, Anemia, Sickle Cell
- VutiglabridinHSG4112Phase 22 trials
Glaceum · Knee Osteoarthritis (Knee OA), Parkinson Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.